Publications
Daniel A. Vallera, PH.D
(Refereed Publications)
Greenup CJ, Vallera DA, Dodd MD, Kolodziej BJ: Anti-tumor cytotoxicity by Poly (A) containing messenger RNA isolated from tumor specific immunogenic RNA. Brit J Cancer, 38:55, 1978
Webster DJT, Cornacoff JB, Vallera DA, Dalmasso JP, Dodd MC. Minton JP: Immunotherapy of a murine sarcoma using specific anti-tumor immune RNA. J of Surg Oncology, 12:213, 1979
Pennline KJ, Evans SB, Nawrocki JE, Rees JC, Johnson CS, Vallera DA, Dodd MD: Release of soluble "blocking" and "suppressor" factors from normal lymphocytes treated with RNA isolated from spleens of tumor-bearing mice. Brit J Cancer, 39:247, 1979
Vallera DA, Pflugfelder U, Schmidtke JR: Lipopolysaccharide-induced immunomodulatin of the generation of CMC. I. Suppression of the development of cytotoxic lymphocytes. J Immunology, 124:635, 1980
Vallera DA, Gamble CE, Schmidtke JR: Lipopolysaccharide-induced immunomodulation of the gereration of CMC. II. Evidence of the involvement of a regulatory B lymphocyte. J Immunology, 124:641, 1980
Maizel SE, Vallera DA, Mentzer SJ, Ferguson RM: The relative immunogenicity of murine tissues in vivo. Current Surgery, 37:435, 1980
Vallera DA, Soderling CCB, Carlson GJ, Kersey JH: Bone marrow transplantation across major histocompatibility barriers in mice: The effect of elimination of T cells from donor grafts by treatment with monoclonal Thy 1.2 plus complement or antibody alone. Transplantation, 31:218, 1981
Vallera DA, Soderling CCB, Carlson GJ, Kersey JH: Bone marrow transplantation across major histocompatibiliy barriers in mice. II. T cell requirement for engraftment in TLI-conditioned recipients. Transplantation 33:243, 1982
Vallera DA, Mentzer SJ, Maizel SE: Tumor sponge implantation: An in vivo method for studying syngeneic, primary antitumor lymphocyte responses. Cancer Research 42:397, 1982
Vallera DA, Soderling CCB, Kersey JH: Bone marrow transplantation across major histocompatibility barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. J Immunology 128:871, 1982
Vallera DA, Filipovich A, Soderling CCB, Kersey JH: Bone marrow transplantation across major histocompatibility barriers in mice. IV. Graft-versus-host disease in TLI-conditioned mice. Immunopathology 23:437, 1982
Vallera DA, Youle RJ, Neville DM Jr., Kersey JH: Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal GVHD by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. J Exp Med 155:949, 1982
Vallera DA, Youle RJ, Neville DM Jr., Soderling CCB, Kersey JH: Monoclonal antibody-toxin conjugates for experimental GVHD prophylaxis. Reagents selectively reactive with T cells and not murine stem cells. Transplantation 36:73, 1982
Vallera DA, Ash RC, Zanjani ED, Kersey JH, LeBien TW, Beverley PCL, Neville DM Jr., Youle RJ: Anti-T cell reagents for human bone marrow transplantation: Ricin linked to three monoclonal antibodies. Science 222:512, 1983
Quinones RR, Youle RJ, Kersey JH, Zanjani ED, Azemove SM, Soderling CCB, LeBien TW, Beverley PCL, Neville DM Jr., Vallera DA: Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: Effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow. J Immunology 132:678, 1984
Vallera DA, Quinones RR, Azemove SM , Soderling CCB: Monoclonal antibody-toxin conjugates reactive against human T lymphocytes: A comparison of antibody linked to intact ricin toxin to antibody linked to ricin A chain. Transplantation 37:387, 1984
17. Stong RC, Youle RJ, Vallera DA: Elimination of clonogenic T-leukemic cells from human bone marrow using anti-M r 65,000 protein immunotoxins. Cancer Research 44:3000, 1984
Filipovich AH, Vallera DA, Youle RJ, Quinones RR, Neville DM Jr., Kersey JH: Ex vivo treatment of donor bone marrow with anti-T cell immunotoxins for the prevention of graft-versus-host disease. Lancet 8375:469, 1984
Weil-Hillman G, Runge W, Jansen FK, Vallera DA: Cytotoxic effect of anti-M r 67,000 protein immunotoxins on human tumors in a nude mouse model. Cancer Research 45:1328, 1985
Uckun FM, Stong RC, Youle RJ, Vallera DA: Combined ex vivo treatment with immunotoxins and mafosfamid: A novel immunochemotherapeutic approach for elimination of neoplastic T-cells from autologous marrow grafts. Jounal of Immunology 134:3504, 1985
Vallera DA, Soderling CCB, Orosz CG: Assessment of immunocompetence by limiting dilution analysis in long-term T cell depletion chimeras transplanted across the MHC barrier. Transplantation 40:311, 1985
Stong RC, Uckun FM, Youle RJ, Kersey JH, Vallera DA: Use of multiple T-cell directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 66:627, 1985
Uckun FM, Azemove SM, Myers DE , Vallera DA: Anti-CD2 (T,p50) intact ricin immunotoxins for GVHD-prophylaxis in allogeneic bone marrow transplantation. Leukemia Research 10:145, 1985
Soderling CCB, Song CW, Blazar BR, Vallera DA: A correlation between conditioning and engraftment in recipients of MHC mismatched T cell depleted murine bone marrow transplants. Journal of Immunology 135:941, 1985
Uckun FM, Vallera DA, Wee S-L: B lymphocyte regulation of human hematopoiesis. Journal of Immunology 135:3817, 1985
LeBien TW, Anderson JM, Vallera DA, Uckun FM: Increased efficacy in selective elimination of leukemic cell line clonogenic cells by a combination of monoclonal antibodies, BA-1, BA-2, BA-3+ complement and mafosfamid (ASTA Z 7557). Leukemia Research 10:139, 1985
Youle RJ, Uckun FM, Vallera DA and Colombatti M: Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. Journal of Immunology 136:93, 1985
Uckun FM, Gajl-Peczalska KJ, Kersey JH, Houston LL, Vallera DA: Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. Journal of Experimental Medicine 163:347, 1986
Blazar BR, Soderling CCB, Vallera DA: Assessment of multi-organ system engraftment by genotypic typing using restriction fragment-length polymorphisms and by phenotypic typing using a microcytotoxicity assay. Journal of Immunology 137:3338, 1986
Manske JM, Buchsbaum DJ, Azemove SM, Hanna DE, D.A.Vallera : Antigenic modulation by anti-CD5 immunotoxins. Journal of Immunology 136:4721, 1986
Pietryga DW, Blazar BR, Soderling CCB, Vallera DA: The effect of T-subset depletion on the incidence of lethal graft-versus-host disease in a murine major histocompatability complex mismatched transplantation system. Transplantation 43:442, 1987
Filipovich AH, Vallera DA, Youle RJ, Haake R, Blazar BR, Arthur D, Neville DM Jr., Ramsay NKC, McGlave P, Kersey JH: Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings: A pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation 44:62, 1987
Weil-Hillman G, Uckun FM, Manske JM, Vallera DA: Combined immunochemotherapy of human solid tumors in nude mice. Cancer Research 47:579, 1987
34. Uckun FM, Gajl-Peczalska K, Myers DE, Kersey JH, Colvin M, Vallera DA: Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: Efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemia marrow progenitor cells. Blood 69:361, 1987
Buchsbaum DJ, Nelson LA, Hanna DE, Vallera DA: Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins. Int J Radiatin Oncology Biol Phys 13:1701, 1987
Uckun FM, Kersey JH, Gajl-Peczalska KJ, Heerema NA, Provisor AJ, Haag D, Gilchrist G, Song CW, Arthur DC, Roloff J, Lampkin B, Greenwood M, DeWald G, Vallera DA: Heterogeneity of cultured leukemic lymphoid progenitor cells from B-cell precursor ALL patients. J Clin Invest 80:639, 1987
Kersey JH, Weisdorf D, Nesbit ME, LeBien TW, Woods WG, McGlave PB, Kim T, Vallera DA, Goldman AI, Bostrom B, Hurd D, Ramsay NKC: Comparison of autologous and allogeneic bone marrow transplantation for treatment of high risk refractory acute lymphoblastic leukemia. New Eng J Med 317:461, 1988
Blazar BR, Widmer MB, Soderling CCB, Urdal DL, Gillis S, Robison LL, Vallera DA: Augmentation of donor bone marrow engraftment in histoincompatible murine recipients by granulocyte macrophage colony-stimulating factor. Blood 71:320, 1988
Blazar BR, Soderling CCB, Koo GC, Vallera DA: Absence of a facilitory role for NK 1.1 positive donor cells in engraftment across a major histocompatibility barrier in mice. Transplantation 45:876, 1988
40. Myers DE, Uckun FM, Ball ED, Vallera DA: Immunotoxins for ex vivo marrow purging in autologous bone marrow transplantation for acute non-lymphocytic leukemia. Transplantation 46:240, 1988
Uckun FM, Myers DE , Ledbetter JA, Swaim SE, Gajl-Peczalska KJ, Vallera DA: Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia. J Immunol 140:2103, 1988
Blazar BR, Soderling CCB, Robison LL, Vallera DA: Short course total lymphoid irradiation combined with total body irradiation to facilitate engraftment of T-cell depleted marrow across a major histocompatibility barrier in mice. Transplantation 46:324, 1988
Vallera DA, Blazar BR: Depressed leukocyte reconstitution and engraftment in murine recipients of T-cell-depleted histoincompatible marrow pretreated with interleukin 3. Transplantation 46:616, 1988
Blazar BR, Widmer MB , Soderling CCB, Gillis S, Vallera DA: Enhanced survival but reduced engraftment in murine recipients of recombinant granulocyte/macrophage colony-stimulating factor following transplantation of T-cell depleted histoincompatible bone marrow. Blood 72:1148, 1988
Manske JM, Buchsbaum DJ, Hanna DE, Vallera DA: Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model. Cancer Research 48:7107, 1988
Myers DE , Uckun FM, Swaim SE, Vallera DA: The effects of aromatic and aliphatic maleimide crosslinkers on anti-CD5 ricin immunotoxins. Journal of Immunol Methods 121:129, 1989
47. Blazar BR, Kersey JH, McGlave PB, Vallera DA, Lasky LC, Haake R, Bostrom B, Weisdorf DR , C. Epstein and Ramsay NKC: In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 73:849, 1989
Manske JM, Buchsbaum DJ, Vallera DA: The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins. Journal of Immunology 142:1755, 1989
Vallera DA, Blazar BR: T cell depletion for graft-versus-host-disease prophylaxis: A perspective on engraftment in mice and humans. Transplantation 47:751, 1989
Uckun FM, Myers DE , Ledbetter JA, Wee S-L, Vallera DA: Cell-type specific cytotoxicity of anti-CD4 and anti-CD8 ricin immunotoxins against human alloreactive T-cell clones. Blood 74:2445, 1989
Blazar BR, Widmer MB , Cosman D, Sassenfeld HM, Vallera DA: Improved survival and leukocyte reconstitution without detrimental effects on engraftment in murine recipients of human recombinant granulocyte colony-stimulating factor following transplantation of T-cell depleted histoincompatible bone marrow. Blood 74:2264, 1989
Blazar BR, Thiele DL , Vallera DA: Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftment. Blood 75:798, 1990
Manske JM, Uckun FM, Myers DE , Vallera DA: Antigenic modulation and toxicity of intact ricin immunotoxins directed against human T-cells. Antibody Immunoconjugates and Radiopharmaceuticals 3:113, 1990
Schmidberger H, L.King, Lasky LC, Vallera DA: Anti-tumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Cancer Research 50:3249, 1990
Paradis K, Sharp HL, Vallera DA, Blazar BR: Kupffer cell engraftment across the major histocompatibility barrier in mice: Bone marrow origin, class II antigen expression, and antigen-presenting capacity. Journal of Pediatric Gastroenterology and Nutrition 11:525, 1990
Filipovich AH, Vallera D, P. M, Polich D, Gajl-Peczalska K, Haake R, Lasky L, Blazar B, Ramsay NKC, Kersey J, Weisdorf D: T cell depletion with anti CD5 immunotoxin in histocompatible bone marrow transplantation: The correlation between residual CD5 negative T cells and subsequent GVHD. Transplantation 50:410, 1990
Uckun FM, Kersey JH, Vallera DA, Ledbetter JA, Weisdorf D, Myers DE, Haake R, Ramsay NKC: Autologous bone marrow transplantation in high risk remission T-lineage ALL using immunotoxins plus 4-HC for marrow purging: I. Application of multiparameter flow cytometry and colony assays for a quantitative analysis of autografts for the presence of residual T-lineage leukemic lymphoid progenitor cells. Blood 79:1723, 1990
Woods GW, Ramsay NKC, Weisdorf DJ, Haake R, Vallera DA, Kim TH, Lasky L, Nesbit ME, Bostrom B, Uckun F, Goldman AI, Kersey JH: Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: Lack of superiority over cyclophosphamide-containing regimens. Bone Marrow Transplantation 6:9, 1990
Vallera DA, Carroll SF, Snover D, Carlson GJ, Blazar BR: Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Blood 77: 182, 1991
Weisdorf DJ, Haake R, Miller WJ, McGlave PB, LeBien TW, Vallera DA, Lasky LC, Kim TH, Peterson BA, Ramsay NKC, Kersey JH, Hurd DD: Autologous bone marrow transplantation for progressive non-hodgkins lymphoma: Bone marrow immunophenoype and in vitro purging. Bone Marrow Transplantation 8:135, 1991
Schmidberger H, Buchsbaum DJ, Blazar BR, Everson P, Vallera DA: Radiotherapy in mice with Yttrium-90 labeled anti-Ly1 monoclonal antibody: Therapy of the T cell lymphoma EL4. Cancer Research 51:1883, 1991
62. Vallera DA, Schmidberger H, Buchsbaum DJ, Everson P, Blazar BR: Radiotherapy in mice with Yttrium-90 labeled anti-Ly1 monoclonal antibody: Therapy of established graft-versus-host disease induced across the major histocompatibility barrier. Cancer Research 15:1891, 1991
Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA: In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T-cell depleted marrow for the promotion of engraftment. Journal of Immunology 147:1492, 1991
Blazar BR, Carroll SF, Vallera DA: Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier following donor graft preincubation with anti-LFA1 immunotoxin. Blood 78: 3093-3102, 1991
Vallera DA, Carroll SF, Brief S, Blazar BR: Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse. Diabetes 41:457, 1992
Blazar BR, Aukermann SL, Vallera DA: Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell depleted allogeneic or non-depleted syngeneic bone marrow transplants. Blood 79:1636, 1992
Blazar BR, Widmer MB , Taylor PA, Vallera DA: Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by adminstration of recombinant human interleukin-1 alpha. Blood 80:1614, 1992
Jansen B, Vallera DA, Jaszcz WB, Nguyen D, Kersey J: Successful treatment of human acute T-cell leukemia in SCID mice using anti-CD7- deglycosylated ricin a-chain immunotoxin DA7. Cancer Research 52:1314, 1992
Howson-Jan K, Matloub YH, Vallera DA, Blazar BR: In utero engraftment of fully H-2 incompatible versus congenic adult bone marrow transferred into non-anemic murine fetal recipients. Transplantation 56:709, 1993
Poss MT, Swanson JL, Telen MJ, Lasky LC, Vallera DA: A Monoclonal Antibody Recognizing a Unique Rh-Related Specificity. Sanguinis 64:231, 1993
Orchard PT, Detrick R, McIvor RS, Gorden K, Dunbar CE, Vallera DA, Abrams J, Nienhuis AW, Blazar BR: Retroviral mediated transfer of the murine IL-3 gene engineered for intracellular retention results in a myeloproliferative syndrome but is associated with circulating IL-3 levels. Experimental Hematology 21:1245, 1993
Blazar BR, Taylor PA, Snover DC , Bluestone JA, Vallera DA: Non-mitogenic anti-CD3F(ab') 2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier. Jounal of Immunology 150:265, 1993
Vallera DA, Taylor PA, Aukerman SL, Blazar BR: Anti-tumor protection from the murine T cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor (M-CSF) and Interleukin-2 (IL-2). Cancer Research 53:4273, 1993
Blazar B, Taylor P, Snover D, Sehgal S, Vallera D: Murine recipients of fully mismatched donor marrow are protected from lethal Graft-Versus-Host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. Jounal of Immunology 151:5726, 1993
Blazar BR, Taylor PA, Vallera DA: In vivor T-cell receptor ligation facilitates alloengraftment and prevents lethal graft-versus-host disease (GVHD) in mice. Bone Marrow Transplantation 12:S38, 1993
Vallera DA, Taylor PA, Sprent J, Blazar BR: Role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249, 1994
Blazar B, Taylor P, Sehgal S, Vallera D : Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell depleted donor marrow. Blood 83:600, 1994
Bergese SD, Pelletier RP, Ohye RG, Vallera DA, Orosz CG: Treatment of mice with anti-CD3 mAb induces endothelial (VCAM-1) expression. Transplantation 57:711, 1994
Blazar BR, Taylor PA, Vallera DA: In vivo or in vitro anti-CD3 chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. Jounal of Immunology 152:3665, 1994
Vallera DA: Immunotoxins: Will Their Clinical Promise Be Fulfilled? Blood 83:309, 1994
Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibillity complex (MHC) barrier in mice. Blood 83:3815, 1994
Blazar BR, Taylor PA, Fitzsimmons W, Vallera DA: FK506 inhibits GVHD and bone marrow graft rejection in murine recipients of major histocompatibility complex (MHC) disparate donor grafts by interfering with mature peripheral T-cell expansion post-transplantation. Journal of Immunology 153:1836, 1994
Blazar BR, Taylor PA, Panoskaltsis-Mortari, Gray GS, Vallera. DA : Co-blockade of the LFA1: ICAM and CD28/CTLA4: B7 Pathways is a Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully MHC Disparate Donor Grafts. Blood 85:2607, 1995
Blazar BR, Taylor PA, Smith S, Vallera DA: Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex (MHC) disparated donor bone marrow grafts. Blood 85:833, 1995
Blazar BR, Taylor PA, Vallera DA : Adult Bone Marrow-Derived Pluripotent Hematopoietic Stem Cells Are Engraftable When Transferred In Utero Into Moderately Anemic Fetal Recipients. Blood 85:842, 1995
Blazar BR, Taylor PA, Gray GS, Vallera DA: The role of T cell subsets inregulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibiliy (miH)-disparate donor inocula. Transplantation 58:1422, 1995
Blazar, BR, Brennan CA, Broxmeyer HE, Vallera DA : Transgenic mice expressing either bovine growth hormone (bGH) or human GH releasing factor (hGRF) have increased splenic progenitor cell colony formation and DNA synthesis in vitro and in vivo. Experimental Hematology 23:1397, 1995
Mathur A, Vallera DA, Taylor PA, Widmer MB, Yang C, Prabhu A, Blazar BR: Effect of IL-4 and IL-7 on reconstitution of bonor B cess in congenic murine bone marrow transplantaion. Bone Marrow Transplantion 16:119, 1994
Bergese S, Pelletier R, Vallera D , Widmer M, Orosz C: Regulation of endothelial VCAM-1 expression in murine cardiac grafts. The American Journal of Pathology, 146:989, 1995
Chan C-H, Blazar BR, Eide CR, Kreitman RJ, Vallera DA: A murine cytokine fusion toxin specifically targeting the murine GM-CSF receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells. Blood 86:2732, 1995
Vallera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR: IL-1 or TNF- antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 60:1371, 1995
Vallera DA, Taylor PA, Panoskaltsis-Mortari A, Blazar BR: Therapy of ongoing graft-versus-host-disease (GVHD) induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab') 2 -RTA (ricin toxin A chain) immunotoxin. Blood 86:4367, 1995
Blazar BR, Taylor PA, Vallera DA: The in utero transfer of adult bone marrow cells into recipients with severe combined immunodeficiency disorder gives rise to lymphoid progeny with T- and B-cell functional capabilities. Blood 86:4353, 1995
Blazar BR, Roopenian DC, Taylor PA, Christianson GJ, Panoskaltsis-Mortari A, Vallera DA: Lack of GVHD across classical single minor histocompatibility (miH) locus barriers. Transplatation 61:619, 1996
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone JA, Vallera DA: Lethal murine graft-versus-host-disease induced by donor expressing T cells with specificity for host nonclassical MHC class Ib antigens. Blood 87:827, 1996
Blazar BR, Taylor PA, Bluestone JA, Vallera DA: Murine expressing T cells affect alloengraftment via the recognition of nonclassical MHC class Ib antigens. Blood 87:4463, 1996
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sehgal S, Vallera DA: In vivo inhibition of cytokine responsiveness and GVHD mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blood 87:4001, 1996
Vallera DA, Taylor PA, Widmer MB , Blazar BR: IL-1 -mediated promotion of long-term alloengraftment and short-term neutrophil expansion does not require the presence of either donor or host T cells. Transplantation 62: 636, 1996
99.Chan CH, Blazar BR, Eide CR, Greenfield L, Krietman RJ, Vallera DA: Reactivity of murine cytokine fusion toxin, DT 390 -mIL-3, with bone marrow progenitor cells. Blood 88:1445, 1996
Vallera DA, Panoskaltsis-Mortari A, Yost C, Ramakrishnan S, Eide CR, Kreitman R, Nicholls PJ, Pennell C, Blazar BR: Anti-graft-versus-host disease effect of DT 390 -anti-CD3sFv, a single chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T cell receptor. Blood 88:2342, 1996
Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Martari A, Gray GS, Korngold R, Vallera DA: The infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host-disease lethality in part via direct effects on CD4+ and CD8+ T cells. Journal of Immunology 157:3250-9, 1996.
Vallera DA, Burns LJ, Frankel AE, Sicheneder AR , Kersey JH: Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. Journal of Immunological Methods 197:69-83, 1996
103.Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, and Vallera DA: Therapy of patients with T-cell lyphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leukemia and Lymphoma 26:287-298, 1997
Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR: The role of B7.1 by murine acute myeloid leukemia cells in the generation and function of a CD8+ T cell line with potent in vivo graft-versus-leukemia (GVL) properties. Blood 89:3477-86, 1997
105.Panoskaltsis-Mortari A, Taylor PA, Yaeger TM, Wangensteen DO,Bitterman PB, Ingbar DH, Vallera DA, Blazar BR: The critical early proinflammatory events associated with idiopathic syndrome in irradiated murine allogenic recipients are due to donor T cell infusion and pot entiated by cyclophosphamide. Journal of Clinical
Investigation 100:1015-1027, 1997
Vallera DA, Panoskaltsis-Mortari A and Blazar BR: Renal dysfunction accounts for the dose limiting toxicity of DT 390 anti-CD3sFv, a potential new recombiant anti-GVHD immunotoxin. Protein Eng. 10: 1071-1076, 1997
Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allsion JP and Vallera DA: CD28/B7 Interactions are required for sustaining the graft-versus-leukemia effect of delayed post-BMT splenocyte infusion in murine recipients of myeloid of lymphoid leukemia cells. Journal of Immunology 159:3460-3473, 1997
Blazar BR, Taylor PA and Vallera DA: CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal GVHD in MCH disparate. Transplantation 64:571-576, 1997
Blazar BR, Jenkins MK, Taylor PA, White J, Panoskaltsis-Mortari A, Korngold R, Vallera DA: Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen. J Immunol. 159: 5821-5833, 1997
Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Yagita H, Bromberg JS and Vallera DA: Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 158: 29-39, 1997
Blazar BR, Taylor PA, Panoskaltasis-Mortari A and Vallera DA: Rapamycin inhibits the generation of graft-versus-host disease and graft-versus-leukemia- causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol. 160: 5355-5365, 1998
Blazar BR, Taylor PA, Noelle RJ, Vallera DA: CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest. 102: 473-482, 1998
Blazar, BR, Taylor PA, McElmurry R, Tian L, Panoskalsis-Mortari A, Lam S, Lees C, Waldschmidt T, Vallera DA: Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer . Blood 92:3949-59,1998.
Panaskalsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host-disease after allogeneic bone marrow transplantation in mice. Blood 15:3960-7, 1998
Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA et al: Differential effects of the asence of interferon-gamma and IL-4 in acute graft-versus-host-disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 102:1742-8, 1998
116.Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Narula S, Smith S RoncarolMG Vallera DA: Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell mediated graft-versus-host diseaseTransplantation. 66:1220-9, 1998.
117.Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Yagita H, Bromberg JS, Vallera DA: A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantation. Blood 92: 4453-63, 1998.
118.Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA: Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 162: 6368-77, 1999.
119. Vallera DA, Seo S-Y, Panoskaltsis-Mortari A, Griffin JD, Blazar BR: Targeting myeloid leukemia with a DT 390 -IL-3 fusion immunotoxin: Ex vivo and in vivo studies in mice. Protein Engineering 12: 779-85, 1999.
120. Vallera DA, Jin N, Baldrica, J, Panoslaltsis-Mortari, A, Chen S-Y, Blazar, BR. Retroviral immunotoxin gene therapy of acute myelogenous leukemia (AML) in mice using cytotoxic T cells (CTL) transduced with an IL-4/diphtheria toxin gene. Cancer Research 60: 976-84, 2000.
Vallera DA, Kuroki D.W., Panoskaltsis-Mortari A, Buchsbaum DJ, Rogers B, and Blazar BR. Molecular modification of a recombinant anti-CD3-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model. Blood. Blood. 2000 Aug 1;96(3):1157-65.
Vallera DA, Jin N, Baldrica J, Panoskaltsis-Mortari A, Chen S-Y, Blazar BR: Retroviral immunotoxin gene therapy of acute myelogenous leukemia (AML) in mice using cytotoxic T cells (CTL) transduced with an IL-4/diphtheria toxin gene. Cancer Research 60: 976, 2000
Vallera DA, Kuroki DW, Panaskaltsis-Mortari A, Buchbaum DJ, Rogers BE, Blazar BR: Molecular modification of a recombinant anti-CD3e immunotoxin by inducing terminal cystein bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model. Blood 96: 1157, 2000
Vallera DA . Gene therapy with immunotoxins. Methods Mol Biol. 2001;166:235-46. 2001
Jin N, Chen W, Blazar BR, Ramakrishnan S, Vallera DA . Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target gene. Hum Gene Ther. 2002 Mar 1;13(4):497-508.
Frankel AE, Beran M, Hogge DE, Powell BL, Thorburn A, Chen YQ, Vallera DA . Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.Exp Hematol. 30:1316-23, 2002
Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA . Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng. May;15(5):419-27, 2002
Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst. Apr 17;94(8):597-606, 2002
Chen H, Shu Y, Lam S, Todhunter DA, Buchsbaum DJ and Vallera DA . Expression and refolding of bivalent single-chain immunotoxins in E. Coli. 94th Annual AACR meeting Abstract published in the Proceedings of the American Association of Cancer Research. In Press. 2003
Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Skubitz KM, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortari A, Kuroki DW, Wagner JE, and Kersey JH. Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium- 90-labeled anti-CD45 antibody in vitro and in vivo in nude mice. Cancer Biotherapy and Radiopharmaceuticals. 18:133-145, 2003
Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR , Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res. 2003;27:79-84.
Invited Publications
Kersey JH, Vallera DA, Soderling C, Warkentin P, Kim T, Levitt S, Nesbit ME, McGlave P, Woods WG, Krivit W, Coccia PF, and Ramsay NKC: Conditioning to reduce graft rejection following allogeneic marrow transplantation. In Biology of Bone Marrow Transplantation Eds.: Gale RP and Cox CF. Academic Press, New York . 29-36, 1980.
2. Vallera DA and Schmidtke JR: Macrophage regulation of anti-tumor cytotoxicity. In Handbook of Cancer Immunology. Ed.: Waters H. Garland Publishing, Inc., Reston , Virginia . 79-111, 1980.
Vallera DA, Kersey JH, Quinones RR, Zanjani ED, Soderling CCB, Azemove SM, LeBien TW, Beverley PCL, Ash RC, Neville, Jr. DM, and Youle RJ: Antibody-ricin conjugates: Purgative reagents for murine and human allogeneic bone marrow transplantation. In Recent Advances in Bone Marrow Transplantation, New Series, Vol. 7. Ed: Gale RP. Alan R. Liss, Inc., New York., 209-222, 1983.
Kersey J, Ramsay N, Vallera DA, Quinones R, McGlave P, and Filipovich A: Prevention and treatment of human acute graft-versus-host disease. In Recent Advances in Bone Marrow Transplantation, New Series, Vol. 7. Ed: Gale RP. Alan R. Liss, Inc., New York , 283-290, 1983.
Neville DM, Jr., Youle RJ, Kersey JH, and Vallera DA: Monoclonal antibody-ricin conjugates for the treatment of graft-versus-host disease. Present and future prospects. In Monoclonal Antibodies and Cancer. The Armand Hammer Cancer Symposium. Eds: Langman R and Delbecco R. Academic Press, New York , 107-116, 1983.
Vallera DA, Kersey JH, Neville DM, Jr., and Youle RJ: Use of monoclonal antibody-ricin conjugates in experimental allogeneic bone marrow transplantation. In Protides of the Biological Fluids, Vol. 31. Ed: Peeters H. Pergamon Press, Oxford . 769-774, 1984.
Vallera DA, Youle RJ, Filipovich AH, Neville DM, Jr., Zanjani ED, Soderling CCB, Azemove SM, and Kersey JH: Immunotoxins and allogeneic bone marrow transplantation for treatment of human leukemia/lymphoma. In Hodgkin's Disease and Non-Hodgkin's Lymphoma: New Perspectives, Vol. 27. UT Clinical conference on Cancer. Eds: Ford RJ, Fuller LM, Hagemeister FB. Raven Press, New York . 397-405, 1984.
Kersey JH, Vallera DA, Ramsay N, Filipovich L, Stong R, LeBien T, Youle R, Neville D, and Beverley P: Monoclonal antibodies for purging bone marrow of acute lymphoblastic leukemia or graft-versus-host producing cells: Antibody plus complement or immunotoxins. Proceedings of the International Symposium on Detection and Treatment of Minimal Residual Disease in Acute Leukemia, 1984.
Kersey JH, Vallera D, Ramsay N, Filipovich A, Youle R, Neville D, Stong R, and LeBien T: Monoclonal antibodies and immunotoxins in bone marrow transplantation: Purging marrow of ALL or GVHD cells with preservation of stem cells. Hamatol Bluttransfus, 29:34, 1985.
Filipovich AH, Vallera DA, Youle RJ, Neville DM, Jr., and Kersey JH: Ex vivo T cell depletion with immunotoxins in allogeneic bone marrow transplantation: The pilot clinical study for the prevention of graft-versus-host disease. Transplant. Proc., 17:442, 1985.
Orosz CG, Soderling CCB, and Vallera DA: Limiting dilution analysis of bone marrow chimera immunocompetence. Transplant. Proc., 17:513, 1985.
Stong RC, Youle RJ, Kersey JH, Zanjani ED, and Vallera DA: Use of a cocktail of monoclonal antibody-intact ricin conjugates to purge human bone marrow of leukemic cells. In Autologous Bone Marrow Transplantation. Eds: Dicke KA, Spitzer G, Zander AR. The University of Texas , M.D. Anderson Hospital and Tumor Institute at Houston . 455-459, 1985.
Kersey JH, LeBien TW, Vallera DA, Filipovich AH, McGlave P, Kim T, and Ramsay N: Allogeneic and autologous marrow transplantation: Ex vivo purging with monoclonal antibody or immunotoxins to remove leukemic cells or to prevent graft-versus-host disease. Second International Symposium on Minimal Residual Disease in Leukemia, Rotterdam , 1985.
Kersey JH, Filipovich AH, Ramsay NKC, McGlave P, Hurd D, Kim T, Youle R, Neville D, and Vallera DA: Antibody-ricin immunotoxins in allogeneic and autologous bone marrow transplantation. In: New Avenues in Developmental Cancer Chemotherapy, Academic Press, N.Y., 291-297, 1985.
Uckun FM, Vallera DA, LeBien TW, Ramsay NC , Filipovich AH, Myers DE , and Kersey JH: Application of monoclonal antibodies to autologous bone marrow transplantation for B-lineage and T-lineage acute lymphoblastic leukemia: Selective elimination of occult neoplastic cells from autologous stem cell grafts prior to reinfusion. In: Clinical Use of Monoclonal Antibodies in Cancer Therapy and Imaging: Current Status, Controversies and Future Directions. ed: Royston I, Dillman R, Carlo D. Martinus Nijhoff Publishing Co., N.Y., 1986.
LeBien TW and Vallera DA: The use of monoclonal antibody cocktails for the ex vivo treatment of bone marrow in autologous and allogeneic bone marrow transplantation. In: Clinical Use of Monoclonal Antibodies in Cancer Therapy and Imaging: Current Status, Controversies and Future Directions. ed: Royston I, Dillman R, Carlo D. Martinus Nijhoff Publishing Co., N.Y., 1986.
Vallera DA: The use of immunotoxins in bone marrow transplantation: Eradication of T cells and leukemic cells. In: Immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer. Ed: C-W. Vogel. Oxford University Press, New York . 217-240, 1987.
Uckun FM, Myers DE , Kersey JH, Filipovich AH, Ramsay NKC, McGlave P, Dickson T, and Vallera DA: Immunotoxins in Bone Marrow Transplantation: An Updated Review of the Minnesota Experience. In: Membrane-Mediated Cytotoxicity, vol. 45, Eds: Bonavida B and Collier RJ, Alan R. Liss, Inc., New York , N.Y. 231-242, 1987.
Uckun FM, Houston LH, and Vallera DA: Pokeweed antiviral protein immuntoxoins and their clinical potential for systemic prophylaxis/treatment of major complications of bone marrow transplantation in acute lymphoblastic leukemia. In: Membrane-Mediated Cytotoxicity, vol. 45, Eds: Bonavida B and Collier RJ, Alan R. Liss, Inc., New York , N.Y. 243-256, 1987.
Blazar BR, Filipovich AH, Kersey JH, Uckun FM, Ramsay NKC, McGlave PB, and Vallera DA: T-cell depletion of donor marrow grafts: Effects on graft-versus-host disease and engraftment. In: Progress in Bone Marrow Transplantation, vol. 53, Eds: Gale RP and Champlin R, Alan R. Liss, Inc. New York . 381-397, 1987.
Uckun FM, LeBien TW, Gajl-Peczalska KJ, Kersey JH, Myers DE , Anderson JM, Dickson TB, and Vallera DA: Ex vivo marrow purging in autologous bone marrow transplantation for acute lymphoblastic leukemia: Use of novel colony assays to test the anti-leukemic efficacy of various strategies. In: Progress in Bone Marrow Transplantation, vol. 53, Eds: Gale RP and Champlin R. Alan R. Liss, Inc., New York , N.Y. 759-771, 1987.
Kersey JH, Weisdorf D, Nesbit M, Woods W, LeBien T, McGlave T, Kim T, Filipovich A, Vallera DA, Haake R, Bostrom B, Hurd D, Krivit W, Goldman A, and Ramsay N: Allogeneic and autologous bone marrow transplantation for acute lymphoblastic leukemia (ALL). In: Progress in Bone Marrow Transplantation, vol. 53, Eds: Gale RP and Champlin R. Alan R. Liss, Inc., New York , N.Y. 77-90, 1987.
Kersey J, Filipovich A, Ramsay N, Uckun F, LeBien T, McGlave P, Blazar B, and Vallera D: Anti T cell immunotoxins for bone marrow purging. Raven Press, 1987.
Vallera DA, Buchsbaum DJ, Uckun FM, Myers DE , and Levitt SH: Labeled monoclonal antibodies for the treatment of cancer: An update from the University of Minnesota . Proceedings of the Fifth Asian-Oceanian Congress of Radiology, 1987.
Kersey JH, LeBien TW, Ramsay NKC, Filipovich AH, McGlave PB, Uckun FM, Blazar BR, and Vallera DA: Antibodies and immunotoxins for bone marrow purging. Bone Marrow Transplantation 2(suppl):47, 1987.
Vallera DA, and Myers DE : Immunotoxins containing ricin. In: Immunotoxins. Ed: Frankel AE. Kluwer Academic Publishers, Boston , MA . 141-159, 1988.
Vallera DA: Immunotoxins for ex vivo bone marrow purging in human bone marrow transplantation. In: Immunotoxins. Ed: Frankel AE. Kluwer Academic Publishers, Boston , MA . 515-535, 1988.
Vallera DA, and Uckun FM: Immunoconjugates. In: Biological Response Modifiers and Cancer Therapy Ed: Chiao JW. Marcel Dekker , New York , 17-50, 1988.
Kim TH, Shank BM, Vallera DA, Travis EL, and Song CW: Immunosuppressive techniques using radiation. Am. J. Clin. Oncol., 11:362, 1988.
Blazar BR, Widmer MB , Kersey JH, Ramsay NKC, McGlave PB, Urdal DL, Gillis S, Henney C, and Vallera DA: Recombinant granulocyte/macrophage-colony stimulating factor in human and murine bone marrow transplantation. Institute Mitleilungen, 83:170, 1988.
Kersey JH, Filipovich A, Ramsay N, Uckun F. LeBien T, McGlave P, Blazar B, Vallera DA: Anti-T cell immunotoxins for bone marrow purging. Proceedings of the International Meeting on Genotypic, Phinotypic and Functional Aspects of Hematopoiesis. Martelli MS, Grignani F, and Reisner Y (eds.) Christiangraf, via Ana Ghina, Rome , 139-142, 1988.
Ramsay N, LeBien T, Weisdorf D, Woods W, Bostrom B, Nesbit M, Vallera DA, Uckun F, Goldman A, Kim T, Haake R, Lasky L, and Kersey J: Autologous BMT for patients with acute lymphoblastic leukemia. In: Bone Marrow Transplantation: Current Controversies, vol. 91. Eds: Gale RP and Champlin R. Alan R. Liss, Inc., New York , 57-66, 1988.
Manske JM, and Vallera DA: Intracellular trafficking of ricin immunotoxins: the role of ricin B chain. In: Trafficking of Bacterial Toxins. Ed: Saelinger CB. CRC Press, Boca Raton , FL , 129-148, 1990.
Vallera DA, Widmer MB , and Blazar BR: T-cell clones in graft-vs.-host disease. In: Graft-versus Host Disease: Immunology, Pathophysiology, and Treatment. Eds: Burakoff SJ, Deeg HJ, Ferrara J, and Atkinson K. Marcel Dekker, Inc., New York, NY, 61-73, 1990.
Weisdorf D, Ramsay N, LeBien T, Woods W, Bostrom B, Nesbit M, Vallera D, Uckun F, Goldman A, Kim T, McGlave P, Hurd D, Haake R, and Kersey J: Allogeneic and autologous bone marrow transplantation for acute lymphoblastic leukemia. In: Haematology and Blood Transfusion: Acute Leukemias II, vol. 33. Eds: Buchner T, Schellong G, Hiddemann W and Ritter J. Springer-Verlag , Berlin , Heidelberg , 679-683, 1990.
Vallera DA, Uckun FM, Kersey JH, Weisdorf DJ, Filipovich AH, Ramsay N, and Lasky LC: Bone marrow purification. In: Monoclonal Antibodies. Eds: Edwards-Moulds J, and Masouredis S. American Association of Blood Banks, Arlington , VA , 181-200, 1990.
Vallera DA and Uckun FM: Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL). Progress in Clin. and Biol. Research, 333:191, 1990.
Vallera DA and Blazar BR: T cell depletion and allogeneic bone marrow transplantation. In: New Strategies in Bone Marrow Transplantation. Eds: Champlin RE, and Gale RP. Wiley-Liss , New York , 29-38, 1991.
Vallera DA and Uckun FM: Autologous bone marrow purging with immunotoxins in acute lymphoblastic leukemia. In: New Strategies in Bone Marrow Transplantation. Eds: Champlin RE and Gale RP. Wiley-Liss , New York , 39-50, 1991.
Blazar BR, Widmer MB , and Vallera DA: Cytokine usage in irradiated animals. In: New Strategies in Bone Marrow Transplantation. Eds: Champlin RE and Gale RP. Wiley-Liss , New York , 349-355, 1991.
Vallera DA and Blazar BR: General strategies in in vivo animal modeling and the future of toxin conjugate research. In: Genetically Engineered Toxins. Ed: Frankel AE. Marcel Dekker , New York , 1992.
Jansen B, Kersey JH, Vallera DA: Immunotoxins: New Anti-Leukemic Agents. In: Clinical Bone Marrow Transplant:ation A Textbook. Ed: Atkinson, K. Cambridge University Press, Cambridge , 604-617, 1992.
Blazar BR, Taylor PA, Sehgal SN, Vallera DA: Rapamycin Prolongs Survival of Murine Recipients of Fully Allogeneic Donor Grafts When Administered During the Graft-Versus-host Disease Process. In: Annals of the New York Academy of Science, 685:73, 1992.
Blazar BR, Vallera DA: Ex Vivo And In Vivo Cytokine Studies In Irradiated Animals. In: Peripheral Blood Stem Cell Autografts. Eds: Wunder/Henon. Springer-Verlag, Heidelberg , 89-95, 1993.
Blazar BR, Taylor PA, Vallera DA: In vivo T-cell receptor ligation facilitates alloengraftment and prevents lethal graft-versus-host disease (GVHD) in mice. Bone Marrow Transplantation. 12:S 38, 1993.
Blazar BR, Vallera DA, Taylor PA, Boyer MW: Can graft-versus-leukemia (GVL) effects be exploited to reduce leukemia associated mortality after bone marrow transplantation (BMT)? Proceedings of Marrow Transplantation in Children, 1995.
Vallera DA: Targeting T cells for GVHD Therapy. Seminars in Cancer Biology. 7:57, 1996.
Kersey J, Davies S, Enright H, Uckun F, Vallera D, Ramsay N, McGlave P: Graft-versus-leukemia, immunotoxins and other targeted biological therapies in bone marrow transplantation. Turkish Journal of Haematology. 1996.
Blazar BR, Korngold R, Vallera DA: Recent advances in graft-versus-host disease (GVHD) prevention. Immunol. Rev. 157:79-109, 1997.
Blazar BR, Vallera DA, Korngold R: Targeting of immunological agents. In: Encylopedia of Immunology, Second Edition; edited by P.J. Delves and I. Roitt, Academic Press Ltd., London UK ; 4: 2261-4, 1998.
Frankel AE, Powell BL, Vallera DA, Neville DM Jr. Chimeric fusion proteins--diphtheria toxin-based. Curr Opin Investig Drugs. 2001;2:1294-301. Review.
Frankel AE, Bugge TH, Liu S, Vallera DA, Leppla SH. Peptide toxins directed at the matrix dissolution systems of cancer cells. Protein Pept Lett. 2002;9:1-14. Review.
Ramage JG, Vallera DA , Black JH, Aplan PD, Kees UR , Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res.27(1):79-84, Jan 2003
Vallera, DA , Jin N, Shu Y, Panoskalatsis-Mortari A, Kelekar A, Chen W. Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene. Hum Gene Ther. 10;14(18):1787-98 Dec. 2003.
Rastamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA . Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol, 65(1):63-75 Review Oct. 2003.
Rastamzadeh E, Low WC, Vallera DA , Hall WA. Immunotoxin therapy for CNS tumor. J Neurooncol, 64(1-2)101-16 Review Aug-Sept 2003.
Vallera DA , Elson M, Breichbiel MW, Dusenbery KE, Burns LJ, Skubitz KM, Jaszca WB, Ramsay NK, Panoskaltisis-Mortari A, Kuroki DW, Wawgner JE, Kersey JH. Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice. Cancer Biother Radiopharm 18(2):133-45 April 2003.
Todhunter DA, Hall WA , Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA . A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel.17(2):157-64 Feb 2004
Vallera DA , Todhunter D, Kuroki D, Shu Y, Sicheneder A, Panoskaltsis-Motari A, Vallera VD, and Chen H. Molecular modification of a recombinant anti-human bivalent CD 3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk Res. 2004. In Press.
Vallera DA , Elson M, Breichbiel MW, Dusenbery KE, Burns LJ, Jaszca WB, Ramsay NK, Panoskaltsis-Mortar A, Kuroki DW, Wagner JE< Vitetta ES, Kersey JH. Radiotherapy of CD 19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm.19(1):11-23 Feb 2004
|
